Literature DB >> 31669642

Long non-coding RNA AFAP1-AS1 promotes proliferation and invasion in prostate cancer via targeting miR-512-3p.

Kai Wang1, Hao Sun2, Tao Sun3, Hongchen Qu1, Qingpeng Xie1, Hang Lv1, Bin Hu4.   

Abstract

BACKGROUND (OBJECTIVE): In the development of tumor therapy, the role of long non-coding RNA actin filagenin 1 antisense RNA 1 (1ncRNA AFAP1-AS1) is quite significant, but the actual role of AFAP1-AS1 in the treatment of prostate cancer has not been determined. In view of this, the author took AFAP1-AS1 as the research object to design an experimental study, and conducted an in-depth exploration of the pathogenesis of prostate cancer.
METHODS: RT-qPCR was used to detect the expression of AFAP1-AS1 and miR-512-3p in prostate cancer tissues and cell lines. Perforation, flow cytometry and CCK-8 were used to detect the effects of cell proliferation, migration and invasion of mir-512-3p and a AFAP1-AS1. And the luciferase reporter gene was used to detect the downstream target gene of AFAP1-AS1, and the expression of CDK4, CDK6 and CCND1 protein was detected by Western blot.
RESULTS: AFAP1-AS1 is highly expressed in prostate cancer tissues and cell lines. The expression level of AFAP1-AS1 is correlated with histological grade and distant metastasis. The overall level of patients with high expression of AFAP1-AS1 is low, and their survival rate is relatively low. Silencing AFAP1-AS1 can significantly increase the proliferation and migration of prostate cancer cells. AFAP1-AS1 silencing induces cell cycle arrest at G0/G1 phase. The downstream target of AFAP1-AS1 was mir-512-3p. The role of AFAP1-AS1 in the progression of prostate cancer cells was mediated by mir-512-3p.
CONCLUSION: AFAP1-AS1 regulates miR-512-3p, so as to realize the regulation effect on the proliferation, invasion and migration of prostate cancer cells, and thereby promote the occurrence and development of prostate cancer, so as to provide the corresponding program for the treatment of prostate cancer. Abberivation: ADPC, androgen-dependent prostate cancer; CRPC, castrated prostate cancer; RNA1 AFAP1-Asl, Actin fiber-associated protein 1-anti-RNA1; miRNAs, MicroRNAs.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AFAP1-AS1; Cell cycle; Proliferation; Prostate cancer; miR-512-3p

Mesh:

Substances:

Year:  2019        PMID: 31669642     DOI: 10.1016/j.gene.2019.144169

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  Identification of Spindle and Kinetochore-Associated Family Genes as Therapeutic Targets and Prognostic Biomarkers in Pancreas Ductal Adenocarcinoma Microenvironment.

Authors:  Yi Liu; Zong-Rui Jin; Xing Huang; Ye-Cheng Che; Qin Liu
Journal:  Front Oncol       Date:  2020-11-02       Impact factor: 6.244

2.  miR-512-3p Overcomes Resistance to Cisplatin in Retinoblastoma by Promoting Apoptosis Induced by Endoplasmic Reticulum Stress.

Authors:  Miao Kong; Yuanyuan Han; Yunhe Zhao; Hong Zhang
Journal:  Med Sci Monit       Date:  2020-07-09

Review 3.  A Review on the Role of AFAP1-AS1 in the Pathoetiology of Cancer.

Authors:  Soudeh Ghafouri-Fard; Tayybeh Khoshbakht; Bashdar Mahmud Hussen; Mohammad Taheri; Majid Mokhtari
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

Review 4.  Crosstalk between Long Non Coding RNAs, microRNAs and DNA Damage Repair in Prostate Cancer: New Therapeutic Opportunities?

Authors:  Folake Orafidiya; Lin Deng; Charlotte Lynne Bevan; Claire Emily Fletcher
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

5.  Circ_0020123 plays an oncogenic role in non-small cell lung cancer depending on the regulation of miR-512-3p/CORO1C.

Authors:  Heng Zhang; Ting Huang; Shisi Yuan; Yuxi Long; Shuai Tan; Guoliang Niu; Puhua Zhang; Meiling Yang
Journal:  Thorac Cancer       Date:  2022-04-07       Impact factor: 3.223

6.  Long non-coding RNA AFAP1-AS1 accelerates the progression of melanoma by targeting miR-653-5p/RAI14 axis.

Authors:  Fei Liu; Lanting Hu; Yi Pei; Ke Zheng; Wei Wang; Shenglong Li; Enduo Qiu; Guanning Shang; Jiaming Zhang; Xiaojing Zhang
Journal:  BMC Cancer       Date:  2020-03-30       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.